Supplementation With Polyphenol-Rich Foods and Atrial Fibrillation After a Cardiac Surgery
NCT ID: NCT02045134
Last Updated: 2018-03-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
50 participants
INTERVENTIONAL
2014-09-30
2015-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Anthocyanin-Rich Table Grape Powder for Prophylaxis of Post-Operative Atrial Fibrillation
NCT05991700
Effect of Polyphenol Extract on Cardiovascular Health Markers: a 4 Way Randomised Crossover Study
NCT05220059
Polyphenols and Endothelial Function
NCT00619749
Effects on Cognitive Functions and Mood of Food Products Rich in Polyphenols
NCT02243956
Effects of Oral Antioxidant Cocktail in Cardiovascular Disease Patients
NCT03629613
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
2. Aim of the study. The main objectives of this project are to evaluate the association between the effect of polyphenol-rich food supplementation and post-operative atrial fibrillation (POAF) in patients undergoing an OHS.
3. Study design: Multicentre, randomized, placebo-controlled double-blind trial with 2 parallel arms: soluble corn flour at high content in anthocyanins and placebo. Placebo consists of soluble corn flour not rich in anthocyanins. The treatment will start at hospital admission until one day before cardiac surgery, and continue (4 days) after extubation and when the patients are reallocated to eat.
4. Study Population and recruitment: A total of 350 consecutive CAD patients undergoing to CABG or VR will be recruited. Participants will be identified at the Department of Cardiovascular disease of the clinical centers.
Eligible subjects will be recruited at their first surgical consultation and subsequently referred to the research investigators. The research staff in charge of the recruitment will pre-screen participants on the basis of inclusion/exclusion criteria and will explain the study at this time.
The main inclusion criteria are :age 18 years or older, presence of sinus rhythm on the screening electrocardiogram, first-time elective open heart surgery. Exclusion criteria are: absence of sinus rhythm at screening, known allergy or intolerance to gluten or anthocyanin compound, regularly consuming of anthocyanin or antioxidant supplements, being currently pregnant, existing or planned cardiac transplant or use of ventricular assist device, or being unable or unwilling to provide informed consent, known history of hepatic or renal disease, cancer and subjects with a history of substance abuse.
Once signed the informed consent, if the subject is eligible for the study according to the inclusion/exclusion criteria, he/she will be included into the trial and randomised, using prepared envelopes blinded to the study investigators, to receive daily high-anthocyanin supplement or placebo.
Subjects will start the dietary intervention at hospital admission until one day before cardiac surgery. Then they will continue the supplementation as soon they are reallocated to eat for the next 4 days after the surgery.
Each patient will be asked to answer electronic questionnaires to collect personal information and medical history (social status, previous disease or surgical interventions, risk factors and family history for cardiovascular disease, drug use). Other relevant clinical data as well as measures of clinical outcomes will be collected by medical records. A 1-year food frequency questionnaire will be used to investigate dietary habits. Electrocardiographic, blood pressure, anthropometric measurements will be collected using standardized methods. During the hospitalization, time in intensive therapy, post-surgical course, specific drug therapy, post-surgical complications, fatal and non-fatal cardiovascular events, re-intervention of revascularization and bypass occlusion will be recorded.
Venous blood (max 30 mL) will be collected before PRFs/placebo supplementation and 24 h and 72 h after the cardiac surgery.
The patients will undergo OHS according to the indication and good practice procedures normally applied in the Department of Cardio-surgery of participant clinical centers.
All patients will receive the pharmacological therapy and the lifestyle change advice according to the best clinical practice for the specific disease and surgical intervention.
5. Evaluation criteria: The primary end point will be the occurrence of postoperative AF of at least 30 seconds' duration and documented by rhythm strip or 12-lead ECG or treated with pharmacological or electrical cardioversion.
6. Power calculation: Fixing alpha=0.05, beta=0.2, the incidence of POAF =38% with a sample size of N=350 CABG patients (half of them will be randomize to PRFs supplementation) and a 22% of drop-out, we can observe a relative risk \<0.64 in reduction of POAF in the intervention group.
7. Statistical analysis. All analyses will be performed using statistical analysis software SAS (SAS, 9.1.3 for Windows, Cary, NC: SAS Institute Inc.1989). All individuals enrolled will be included in the analysis. Descriptive summaries will be presented for all the individuals, and for subgroups of individuals. Statistical tests will be carried out for exploratory purposes, as appropriate. The descriptive analysis of nominal/ordinal data will comprise tabulation of frequency and percentages. Chi-square test (or Fisher exact test in the presence of small frequencies) will be used to compare categories. The descriptive analysis of continuous data will comprise the mean, standard deviation, median, extreme values, and 95% confidence interval. OHS patients will be randomized to receive a short term supplementation of PRFs or placebo (J Nutr 2008), following the scheme of a controlled randomised double-blind clinical trial. POAF occurence will be compared in PRFs supplemented and control groups to assess the efficacy and safety of the intervention. The "intention to treat" principle will be adopted for the analysis of the combined endpoints.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Soluble corn flour not rich in anthocyanins
Placebo
Soluble corn flour not rich in anthocyanins
High-anthocyanin rich corn flour
Soluble corn flour at high content in anthocyanins
High-anthocyanin rich corn flour
Soluble corn flour at high content in anthocyanins
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
Soluble corn flour not rich in anthocyanins
High-anthocyanin rich corn flour
Soluble corn flour at high content in anthocyanins
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* first-time elective open heart surgery
Exclusion Criteria
* known allergy or intolerance to gluten or anthocyanin compound
* regularly consuming of anthocyanin or antioxidant supplements,
* being currently pregnant,
* existing or planned cardiac transplant or use of ventricular assist device,
* being unable or unwilling to provide informed consent,
* history of hepatic or renal disease,
* history of cancer history of substance abuse
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Neuromed IRCCS
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Licia Iacoviello
Laboratory Head
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Licia Iacoviello, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
IRCCS INM Neuromed, Department of Epidemiology and Prevention
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
IRCCS INM Neuromed, Department of Epidemiology and Prevention
Pozzilli, IS, Italy
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Costanzo S, di Niro V, Di Castelnuovo A, Gianfagna F, Donati MB, de Gaetano G, Iacoviello L. Prevention of postoperative atrial fibrillation in open heart surgery patients by preoperative supplementation of n-3 polyunsaturated fatty acids: an updated meta-analysis. J Thorac Cardiovasc Surg. 2013 Oct;146(4):906-11. doi: 10.1016/j.jtcvs.2013.03.015. Epub 2013 Apr 12.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Neuromed-GR-2008-1146478
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.